Avalon GloboCare CEO David Jin, M.D., Ph.D. to Chair and Speak at the Plenary Session of the 14th Annual World Stem Cell Summ...
January 15 2019 - 8:00AM
Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer
of cell-based technologies, announced today that its President and
Chief Executive Officer, David Jin, M.D., Ph.D., will chair and
speak at the plenary session of the 14th Annual World Stem Cell
Summit in Miami, Florida. The presentation is entitled,
"Status of Cellular Therapy and Regenerative Medicine in China."
Session information: |
Date: |
|
January
24, 2019 |
Time: |
|
9:20 a.m.
ET |
Venue: |
|
Hyatt
Regency Miami |
"Avalon GloboCare is dedicated to assembling and integrating the
premier scientific, clinical, and regulatory resources from around
the world, in order to accelerate innovative and transformative
cellular technologies and their clinical applications," stated Dr.
David Jin. "We are honored to lead a panel with leading experts
from the U.S. and China to discuss an evolving ecosystem of
cellular therapy and regenerative medicine. We look forward to
sharing our experiences and capabilities in cell-based technologies
and therapeutics," added Dr. Jin.
The 2019 World Stem Cell Summit is the global, super-ecosystem
event, trans-disciplinary in scope. The Summit is designed to
breakdown silos, expand scientific/clinical knowledge and forge
collaborations, with the overarching collective goal to improve
health and deliver cures. For more information please
visit: http://www.worldstemcellsummit.com
About Avalon GloboCare
Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent
biotech developer and healthcare service provider dedicated to
advancing cell-based technologies and therapeutics, with a focus on
developing and empowering innovative and transformative cell-based
technologies and their clinical applications. In addition,
Avalon provides strategic advisory and outsourcing services to
facilitate and enhance its clients' growth, development, as well as
competitiveness in both the domestic and global healthcare
markets. Through its subsidiaries, namely GenExosome
Technologies Inc. and Avactis Biosciences Inc., Avalon is
establishing a leading role in the fields of exosome-based
diagnostics, cellular immunotherapy (including CAR-T/CAR-NK), and
regenerative medicine.
About the World Stem Cell Summit
Produced by the 501(c)(3) non-profit Regenerative Medicine
Foundation (RMF), and in its 14th year, the World Stem Cell Summit
2019 is co-located with the Phacilitate Leaders World 2019. It is
the most inclusive and expansive interdisciplinary, networking, and
partnering meeting in the stem cell science, cellular therapy and
regenerative medicine field. With the overarching purpose of
fostering biomedical research, funding, and investments targeting
cures, the Summit is the single conference serving the diverse
ecosystem of stakeholders.
Forward-Looking Statements
Certain statements contained in this press
release may constitute "forward-looking
statements." Forward-looking statements provide current
expectations of future events based on certain assumptions and
include any statement that does not directly relate to any
historical or current fact. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors as disclosed in our filings with the
Securities and Exchange Commission located at their website
(http://www.sec.gov). In addition to these factors, actual future
performance, outcomes, and results may differ materially because of
more general factors including (without limitation) general
industry and market conditions and growth rates, economic
conditions, and governmental and public policy changes. The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the
date of the press release.
Contact Information: Avalon GloboCare
Corp. 4400 Route 9, Suite 3100 Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations: Crescendo Communications,
LLC Tel: (212) 671-1020 avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Apr 2023 to Apr 2024